Danaher Co. (NYSE:DHR) Shares Sold by Westwood Holdings Group Inc.

Westwood Holdings Group Inc. lessened its holdings in Danaher Co. (NYSE:DHR) by 0.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 327,199 shares of the conglomerate’s stock after selling 820 shares during the period. Westwood Holdings Group Inc.’s holdings in Danaher were worth $81,751,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Cape Investment Advisory Inc. purchased a new position in shares of Danaher during the fourth quarter worth about $25,000. Tsfg LLC increased its position in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher in the second quarter valued at about $25,000. nVerses Capital LLC purchased a new position in Danaher during the second quarter worth $25,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in Danaher during the 1st quarter worth about $30,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 over the last three months. Corporate insiders own 11.10% of the company’s stock.

Danaher Trading Down 1.4 %

Shares of NYSE DHR opened at $272.63 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The business has a 50-day moving average price of $267.62 and a two-hundred day moving average price of $257.14. The firm has a market capitalization of $201.93 billion, a PE ratio of 46.21, a PEG ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the firm earned $2.05 EPS. The company’s revenue was down 2.9% compared to the same quarter last year. As a group, analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Jefferies Financial Group initiated coverage on Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price on the stock. Wells Fargo & Company began coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. Robert W. Baird increased their price objective on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, Evercore ISI cut their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.